Observational, Postmarketing Surveillance Study of Spinraza Injection (Nusinersen Sodium)
← catalyst calendarNCT04317794 · readout in 170 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
74actual
Sites
16
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-07-02 | actual | When the study began enrolling |
| Primary completion | 2027-02-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-05 | estimated | The whole study's end, after follow-up |
| First posted | 2020-03-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Muscular Atrophy, Spinal
Intervention
- Drug: Nusinersen Sodium Injection — also filed as BIIB058, ISIS 396443, Spinraza
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
measured Up to End of Treatment (2 Years)
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed